FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and can be used for treating ocular diseases associated with amyloid-beta related pathological abnormalities/changes in the visual system tissues. That is ensured by administering a pharmaceutical composition, which contains a therapeutically effective amount of a humanised antibody or antigen-binding fragment, wherein the humanised antibody or its fragment is able to bind amyloid-beta. Presented are preventing, treating or relieving symptoms of an ocular disease, reducing the plaque load of retinal ganglion cells, diagnosing the ocular disease and diagnosing a predisposition to the ocular disease, prolonging the patient's sensitivity when treating with the pharmaceutical composition for treating the ocular disease.
EFFECT: group of inventions provides the effective treating of the above ocular pathology by using the composition containing the high-specific antibodies, which specifically recognise and bind to specific epitopes of various β-amyloid proteins.
20 cl, 18 dwg, 9 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2542967C2 |
| HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
| USE OF ANTI-BETA AMYLOID ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2482876C2 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2604181C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF AMYLOIDOSES | 2018 |
|
RU2746812C1 |
| PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY | 2008 |
|
RU2523894C2 |
| ANTI-AMYLOID BETA (A BETA) 1-42 MONOCLONAL ANTIBODIES POSSESSING THERAPEUTIC PROPERTIES | 2006 |
|
RU2551782C2 |
